{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T12:46:11Z","timestamp":1767962771676,"version":"3.49.0"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["curr pharm des"],"published-print":{"date-parts":[[2012,8,1]]},"DOI":"10.2174\/138161212801227005","type":"journal-article","created":{"date-parts":[[2012,6,26]],"date-time":"2012-06-26T17:50:33Z","timestamp":1340733033000},"page":"3373-3388","source":"Crossref","is-referenced-by-count":31,"title":["Purine Nucleoside Analogs in the Treatment of Rarer Chronic Lymphoid Leukemias"],"prefix":"10.2174","volume":"18","author":[{"given":"Tadeusz","family":"Robak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pawel","family":"Robak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","container-title":["Current Pharmaceutical Design"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/99702","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2015,11,20]],"date-time":"2015-11-20T14:24:02Z","timestamp":1448029442000},"score":1,"resource":{"primary":{"URL":"http:\/\/openurl.ingenta.com\/content\/xref?genre=article&issn=1381-6128&volume=18&issue=23&spage=3373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,1]]},"references-count":0,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2012,8,1]]}},"alternative-id":["1381-6128(20120801)18:23L.3373;1-"],"URL":"https:\/\/doi.org\/10.2174\/138161212801227005","relation":{},"ISSN":["1381-6128"],"issn-type":[{"value":"1381-6128","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8,1]]}}}